Alkermes plc (NASDAQ:ALKS) Shares Sold by New York Life Investment Management LLC

New York Life Investment Management LLC lowered its position in shares of Alkermes plc (NASDAQ:ALKSFree Report) by 13.7% in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 12,630 shares of the company’s stock after selling 2,003 shares during the quarter. New York Life Investment Management LLC’s holdings in Alkermes were worth $354,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Signaturefd LLC lifted its position in shares of Alkermes by 121.2% in the second quarter. Signaturefd LLC now owns 854 shares of the company’s stock valued at $27,000 after acquiring an additional 468 shares in the last quarter. Emerald Advisers LLC purchased a new position in Alkermes in the 3rd quarter valued at about $27,000. Neo Ivy Capital Management acquired a new stake in shares of Alkermes during the 2nd quarter worth about $27,000. CWM LLC grew its holdings in shares of Alkermes by 147.5% during the third quarter. CWM LLC now owns 1,037 shares of the company’s stock worth $29,000 after buying an additional 618 shares in the last quarter. Finally, Castleview Partners LLC acquired a new position in shares of Alkermes in the second quarter valued at approximately $38,000. Institutional investors and hedge funds own 95.21% of the company’s stock.

Alkermes Stock Performance

Alkermes stock opened at $28.52 on Tuesday. The company has a market cap of $4.76 billion, a PE ratio of 23.00 and a beta of 0.55. The company has a fifty day moving average price of $27.62 and a two-hundred day moving average price of $27.31. Alkermes plc has a 12 month low of $22.01 and a 12 month high of $33.71. The company has a debt-to-equity ratio of 0.21, a current ratio of 2.91 and a quick ratio of 2.53.

Analysts Set New Price Targets

A number of brokerages recently issued reports on ALKS. JPMorgan Chase & Co. restated a “neutral” rating and set a $33.00 target price on shares of Alkermes in a research report on Monday, November 20th. UBS Group assumed coverage on Alkermes in a research note on Tuesday, October 17th. They issued a “neutral” rating and a $31.00 target price for the company. Mizuho reduced their target price on Alkermes from $37.00 to $35.00 and set a “buy” rating on the stock in a research report on Thursday, October 26th. Evercore ISI upgraded Alkermes from an “in-line” rating to an “outperform” rating in a report on Tuesday, October 24th. Finally, lowered shares of Alkermes from a “strong-buy” rating to a “buy” rating in a report on Monday, February 5th. Four investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $32.43.

Check Out Our Latest Stock Analysis on Alkermes

Alkermes Company Profile

(Free Report)

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in the fields of neuroscience and oncology in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of product candidates in development for neurological disorders and cancer.

See Also

Want to see what other hedge funds are holding ALKS? Visit to get the latest 13F filings and insider trades for Alkermes plc (NASDAQ:ALKSFree Report).

Institutional Ownership by Quarter for Alkermes (NASDAQ:ALKS)

Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with's FREE daily email newsletter.